Novartis Ag (NVSEF) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to 436.71%.
- Novartis Ag's EBIT Margin rose 4098800.0% to 436.71% in Q4 2025 from the same period last year, while for Dec 2025 it was 536.94%, marking a year-over-year increase of 5080400.0%. This contributed to the annual value of 32.36% for FY2025, which is 34500.0% up from last year.
- Per Novartis Ag's latest filing, its EBIT Margin stood at 436.71% for Q4 2025, which was up 4098800.0% from 616.58% recorded in Q3 2025.
- Novartis Ag's EBIT Margin's 5-year high stood at 709.74% during Q1 2025, with a 5-year trough of 14.96% in Q3 2023.
- Its 5-year average for EBIT Margin is 129.36%, with a median of 24.68% in 2021.
- In the last 5 years, Novartis Ag's EBIT Margin plummeted by -94200bps in 2022 and then skyrocketed by 6812300bps in 2025.
- Quarter analysis of 5 years shows Novartis Ag's EBIT Margin stood at 19.37% in 2021, then decreased by -14bps to 16.59% in 2022, then surged by 36bps to 22.6% in 2023, then rose by 19bps to 26.84% in 2024, then soared by 1527bps to 436.71% in 2025.
- Its last three reported values are 436.71% in Q4 2025, 616.58% for Q3 2025, and 454.15% during Q2 2025.